MTO1 and central nervous system cancer: TRMT2B, NSUN4, TFB1M, MRM3, MRM2, TRMT112, TRMT61B, TRMT1, PUS1, METTL8, GTPBP3, MTO1, YRDC, NSUN2, and TRMT6 were upregulated in grade III glioma, whereas METTL6 was downregulated in grade II glioma in the TCGA cohort (Fig. S4A).